OS of adult patients with previously untreated AML. Distributions of OS were estimated by the method of Kaplan and Meier. Tickmarks indicate censored values. (A) OS by quartile of sVCAM-1 binding, based on 103 patients with sVCAM-1–binding data. The P value was .023 for the trend (2-sided P value based on logistic regression). (B) OS by age, based on all 175 patients included in this study. (C) OS by cytogenetic risk group, based on 92 patients with evaluable cytogenetics. Note that the 5-year survival data for the highest quartile of sVCAM-1 binding are comparable with the 5-year survival of the youngest patients, with age younger than 40 years.